for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Cabaletta Bio Inc

CABA.OQ

Latest Trade

14.22USD

Change

1.46(+11.44%)

Volume

41,998

Today's Range

12.71

 - 

14.72

52 Week Range

5.55

 - 

19.63

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
12.76
Open
12.71
Volume
41,998
3M AVG Volume
1.90
Today's High
14.72
Today's Low
12.71
52 Week High
19.63
52 Week Low
5.55
Shares Out (MIL)
24.06
Market Cap (MIL)
306.95
Forward P/E
-9.66
Dividend (Yield %)
--

Next Event

Cabaletta Bio Inc Annual Shareholders Meeting

Latest Developments

More

Cabaletta Bio Files For Offering Of $75 Mln Of Common Stock - SEC Filing

Cabaletta Bio Inc Files For Mixed Shelf Of Upto $250 Mln

Cabaletta Bio Reports Third Quarter 2020 Financial Results And Provides Business Update

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Cabaletta Bio Inc

Cabaletta Bio Inc. is a clinical stage biotechnology company. The Company is focused on discovery and development of engineered T-cell therapies for B cell-mediated autoimmune diseases. The T cells are designed to selectively bind and eliminate B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. The Company’s lead CAAR T cell product candidate are designed based on chimeric antigen receptor, and its T cell technology has been developed and is marketed for the treatment of B cell cancers. The Company has discovered and developed four product candidates, including its lead product candidate, to potentially treat patients with mucosal pemphigus vulgaris (mPV), and three additional product candidates that have demonstrated specific and selective target engagement in vitro. Its product pipelines include DSG3-CAART, DSG3/1-CAART, Musk-CAART and FVIII-CAART.

Industry

Biotechnology & Drugs

Contact Info

2929 Arch St Ste 600

PHILADELPHIA, PA

19104-2857

United States

+1.267.7593100

https://www.cabalettabio.com/

Executive Leadership

Steven Nichtberger

Chairman of the Board, President, Chief Executive Officer, Co-Founder

Anup Marda

Chief Financial Officer

Gwendolyn Knowlton Binder-Scholl

Executive Vice President, Science & Technology

J. Brian Stalter

General Counsel

David J. Chang

Chief Medical Officer

Key Stats

2.00 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2019

0.0K

2020(E)

0.0K
EPS (USD)

2019

-4.070

2020(E)

-1.395
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
2.61
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-31.08
Return on Equity (TTM)
-29.92

Latest News

Latest News

BRIEF-Cabaletta Bio, Artisan Bio Announce Gene Editing Research And Collaboration Agreement To Develop Next-Generation Caar T Cell Therapies

* CABALETTA BIO AND ARTISAN BIO ANNOUNCE GENE EDITING RESEARCH AND COLLABORATION AGREEMENT TO DEVELOP NEXT-GENERATION CAAR T CELL THERAPIES

BRIEF-Cabaletta Bio Announces Expansion Of Sponsored Research Agreement With The University Of Pennsylvania

* CABALETTA BIO ANNOUNCES EXPANSION OF SPONSORED RESEARCH AGREEMENT WITH THE UNIVERSITY OF PENNSYLVANIA

BRIEF-Cabaletta Bio Receives FDA Fast Track Designation For DSG3-CAART For The Treatment Of Mucosal Pemphigus Vulgaris

* CABALETTA BIO RECEIVES FDA FAST TRACK DESIGNATION FOR DSG3-CAART FOR THE TREATMENT OF MUCOSAL PEMPHIGUS VULGARIS

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up